SLC5A2 and heart failure: The aggregated evidence from five randomized trials suggests that SGLT2 inhibitors confer meaningful clinical benefits in HFpEF, including a ~25% reduction in heart failure hospitalizations (HR 0.75; 95% CI 0.68-0.83) and a 5-7-point gain in KCCQ score, both statistically significant.